1. Generics Bulletin
  2. >>Products

FDA Outlines Its Role As Drug Shortages Reach All-Time High

323 Drugs Were Reported To Be In Short Supply In Q1 2024

 
• By Urtė Fultinavičiūtė

The FDA’s Drug Shortage Staff said it aims to resolve long-term, not just short-term, issues with drug supplies, as the country sees the highest-ever levels of drug shortages.

Hands reaching a vaccine vial representing demand
• Source: Shutterstock

The ongoing drug shortage crisis in the US has reached new heights. In the first quarter of 2024, 323 medicines were in short supply, making it the highest level since 2001 or when the American Society of Health-System Pharmacists started tracking these trends. 

These figures were recently reported by the American news website Axios in a graph showcasing active drug shortages in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Generic Drug Office’s Policy Staff Returning To US FDA

 
• By Derrick Gingery

The group had been laid off as part of the 1 April reduction-in-force, which lead to missed guidance publication deadlines.

Stelara Biosimilar Sees Stada’s Specialty Sales Start Strong In Q1

 
• By Dave Wallace

Stada’s Specialty division was boosted by the firm’s launch last year of a European Stelara biosimilar, even as generics growth remained muted in Q1.

Formycon Snatches Brazilian Approval For Lucentis Biosimilar

 
• By Urtė Fultinavičiūtė

Formycon is preparing to start a new era – entering Latin America with its ranibizumab biosimilar, which is expected to be a “good contributor” to the firm’s finances.